| INTRODUCTION
Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion.
1,2 H-K-ATPase constitutes the final pathway through which HCl is secreted into the gastric lumen, where it hydrolyses dietary proteins as well as maintains a sterile environment. 1 PPIs inhibit H-K-ATPase 1 and substantially reduce acid secretion with a long duration of action. 3, 4 Consequently, PPIs are commonly prescribed for patients with gastro-oesophageal reflux disease (GERD), peptic oesophagitis and oesophagitis-associated symptoms. 3, 4 One of the clinical consequences of strong and long-term acid suppression is hypergastrinemia. The resultant hypergastrinemia increases the risk of cancer development. 5 First, hyperplasia of ente-
rochromaffin-like cells (ECL cells) was observed in rodents receiving
PPIs, 6 leading to gastric carcinoid tumours. Although gastric carcinoid tumours have not been detected in humans since the introduction of PPIs, hyperplasia of ECL cells was observed in clinical studies. 7 Moreover, fundic gland polyposis was observed in patients receiving potent and prolonged antisecretory therapy. 8 In addition to cancer observed in the stomach, hypergastrinemia in PPI users was associated with pancreatic cancer, 9 periampullary cancers, 5 colorectal cancer, 10 lung cancer 11 and ovarian cancer. 12 Reports on the hepatotoxicity of PPIs are scarce in the literature. [13] [14] [15] However, a recent study used genome-wide transcriptional expression data from cultured human cells treated with bioactive molecules to study the carcinogenic effect of compounds on the human liver. 16 A PPI was reported to exhibit a notable genetic expression similar to well-known carcinogens in the liver; 16, 17 however, its carcinogenicity remains unknown. Moreover, PPIs allow the proliferation of cells with fatal mutations, and they thus increase the risks of cancers. 18 The mechanism is probably indirect and involves the induction of oxidative stress and production of reactive oxygen species that further damage DNA. Repeated DNA damage likely increases the mutation rate, including that of tumour suppressor genes and oncogenes. 19 The mutation burden engendered by dosedependent PPI use in tumour suppressor genes and oncogenes might affect the onset of hepatocellular carcinoma (HCC). 20, 21 In addition to the reported association between HCC risk and PPI use at the molecular level, we hypothesised that PPI use increases the risk of HCC. In this study, we examined the association between PPI use and the risk of HCC and the impact of long-term PPI use.
| PATIENTS AND METHODS

| Methods
| Data source
We conducted a nested case-control study by using the Taiwan National Health Insurance Research Database (NHIRD). The NHIRD includes all medical claims data on disease diagnoses, procedures, drug prescription, demographics and enrolment profiles of all National Health Insurance (NHI) beneficiaries. 22 The NHI programme covers a geographically representative sample of more than 99% of the population in Taiwan and has approximately 25.7 million insurers. The NHIRD data are additionally linked with the Death Registry to ascertain the vital status and cause of death of each patient.
| Study cohort
We assembled a study cohort comprising patients who were enrolled 
| Selection of cases and controls
The cases comprised 29 473 individuals in the study cohort who received their first diagnosis of HCC at least 1 y after the beginning of their follow-up. Our case definition was patients who were diagnosed as having primary malignancy of the liver. We did not include those diagnosed as having intrahepatic bile duct tumours or whose primary tumours were not specified. The diagnosis of HCC was ness Database, which is a part of the NHIRD. 23 By using the incidence density sampling approach, we selected controls for each HCC case matched according to age within 2 y, sex and duration of follow-up from cohort entry to the date of cancer diagnosis of the cases. We randomly selected up to 10 controls from each risk set assembled using the matching criteria for each case.
| Exposure to PPIs
PPI use before the diagnosis date of HCC was our primary exposure of interest. The prescriptions for PPIs were abstracted from the pharmaceutical claims data of the NHIRD by using the Anatomical Therapeutic Chemical (ATC) classification system. In accordance with the ATC classification system, we selected omeprazole, dexlansopra- 
| Study covariates
Previous and coexisting medical conditions and medication were included in the study to adjust for potential confounding effects. 
| Statistical analysis
The baseline characteristics of patients in the case and control groups are presented. The differences in patient characteristics between the case and control groups were compared using the v To further identify factors that may modify the effect of PPI use on the risk of HCC, we repeated the sampling process and produced 10 additional sets of case-control data. First, we included variables demonstrated in the literature, which may modify the risk of HCC or the likelihood of receiving PPIs, and we added the interaction term to the complete model. We further selected significant variables in the model for matching. Along with the existing matching variables sex and follow-up duration, we included the selected variables into the matching criteria one for each and generated 10 sets of casecontrol data. The variables included in the matching criteria were status of cirrhosis, diabetes, hyperlipidaemia, H. pylori eradication therapy and GERD. Conditional logistic regressions were performed on these data adjusted for variables that were not included in the matching criteria. Finally, we performed a sensitivity analysis to measure the potential influence of an unmeasured confounder on the OR estimates. In addition, we conducted 2 negative control studies to ensure the specificity of the association between PPIs and HCC.
First, we examined the association between kidney cancer and PPIs because the risk factors for kidney cancer and HCC, such as alcohol intake, obesity and high BMI, are similar. 24 Second, we examined the association between head and neck cancer and PPI.
Descriptive analysis and incidence density matching were performed using SAS statistical software (v9.4, SAS Institute, Cary, NC, USA). A sensitivity analysis was conducted using Microsoft Excel.
Statistical significance was set at 0.05, and all tests were 2-tailed.
This study was reviewed and approved by the Institutional Review
Board of Taipei Medical University (TMU-JIRB No. 201402018).
| RESULTS
| Patient characteristics
A total of 29 473 HCC cases were matched with 294 508 controls, and each case was matched with at least 1 eligible control (Table 1 ).
In the study cohort, more than 50% of the patients in the case and control groups were older than 60 y at the time of inclusion, and 68% of them were men. The mean follow-up duration was 60 mo (standard deviation = 48). Patients in the case group were more likely to be diagnosed as having diabetes, peptic ulcer disease, GERD and cirrhosis, compared with their matched controls. The cases were also more likely to receive medication than the controls. cDDDs of PPIs, after adjustment for the covariates listed in Table 2 .
| Risk of HCC
Patients who were diagnosed as having hypertension, diabetes, COPD, cerebrovascular accident, peptic ulcer disease, GERD or cirrhosis or received H. pylori eradication therapy, H2-receptor antagonists or aspirin were associated with a significantly increased risk of HCC, compared with those without these conditions or medications.
In the second multivariate model examining the dose-response association between PPI use and the risk of HCC ( 
| Matching by potential confounders
We sampled different sets of case-control pairs by including the status of cirrhosis, diabetes, hyperlipidaemia, H. pylori eradication therapy and GERD in order to eliminate the potential effects of these factors on the association between PPI use and the risk of HCC ( 
| Sensitivity analysis
We used the prevalence of smoking and obesity reported in 2 previous studies 25, 26 to estimate the effects of potential unmeasured confounders on the OR of HCC risk (Table S1 ). Our sensitivity analysis was based on the base estimates for PPI users vs non-PPI users ( (Table S2 ).
| DISCUSSION
By using a large population-based cohort of more than 200 000 patients, we discovered that PPI use was associated with an overall 2.86 times higher risk of HCC relative to non-PPI use, and an increased risk was associated with the PPI dose. Our study results raise concerns regarding the safety of long-term PPI use, particularly Adjusted odds ratio was estimated from multivariate conditional logistic regression. Other covariates included in the model were hypertension, diabetes, chronic obstructive pulmonary disease, acute coronary syndrome, cerebrovascular accident, peptic ulcer disease, gastro-oesophageal reflux disease, cirrhosis and hyperlipidaemia.
in patients with gastric acid-related disorders such as GERD who might take a PPI indefinitely.
Evidence of the effect of PPIs on the occurrence of HCC is rare in the literature. In this large-cohort study, an association between PPI use and the risk of HCC was certainly observed. Although few studies in the literature have addressed the possible hepatotoxic effect of PPIs, [13] [14] [15] we believe that the hepatotoxic effect should be of limited significance, whereas PPI-induced hypergastrinemia may probably play a stronger role in explaining the association between PPI use and the risk of HCC. Only 1 case-control study in Taiwan The base model included cirrhosis, hypertension, diabetes, chronic obstructive pulmonary disease, acute coronary syndrome, cerebrovascular accident, peptic ulcer disease, gastro-oesophageal reflux disease, hyperlipidaemia, H. pylori eradication therapy, H2-receptor antagonists, aspirin and NSAIDs. In each condition-matched population, the variable being matched was excluded from the base model. PPI, proton pump inhibitor; GERD, gastro-oesophageal reflux disease; NSAIDs, nonsteroidal anti-inflammatory drugs; 95% CI, 95% confidence interval. a Adjusted odds ratio was estimated using multivariate conditional logistic regression. [33] [34] [35] [36] In the present study, we included patients with incident HCC that was not virally induced. These patients represent approximately 15%-20% of the total patients with HCC in Taiwan. In Taiwan, the prevalence of viral hepatitis B has decreased owing to the successful vaccination programme, and thus, the proportion of hepatitis B-associated HCC is decreasing. 37 Therefore, the nonviral factors associated with the development of HCC are crucial. Several strengths of this study are noteworthy. This was a large patient cohort study with a relatively long follow-up duration, which provides a unique opportunity to evaluate the long-term safety of the drugs. Second, we adapted the incidence density sampling method and a nested case-control design, which provided relatively unbiased results in the observational study. This design prevents the effect of time bias, which is crucial for evaluating drug effects. Third, a strong dose-response relationship strengthens the association between PPI exposure and HCC. Fourth, the results from our confounder-matching and sensitivity analyses were both robust and supported the main findings. Finally, 2 negative control analyses demonstrated the specificity of the association between PPIs and HCC.
| CONCLUSION S
This observational study demonstrated that PPIs might increase the risk of HCC. However, additional investigations are warranted to determine whether the increased cancer risk is associated with the stimulation of DNA-damaged cells or whether any symptom before liver cancer diagnosis is associated with an increased prescription of
PPIs. In addition, identifying potential high-risk groups with longterm PPI use might help to maintain the risk-benefit ratio of the treatment.
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